Content about HYDERABAD

September 20, 2012

Drug maker Dr. Reddy's Labs has launched a generic antibiotic drug, the company said Thursday.

HYDERABAD, India — Drug maker Dr. Reddy's Labs has launched a generic antibiotic drug, the company said Thursday.

The India-based company announced the launch of amoxicillin tablets, capsules and oral suspension. The tablets are being launched in the 500-mg and 875-mg strengths, while the capsules are in the 250-mg and 500-mg strengths, and the oral suspension is in the 125-mg-, 200-mg-, 250-mg- and 400-mg-per-5-mL strengths.

September 11, 2012

Generic drug maker Dr. Reddy's Labs has launched a generic drug for treating high blood pressure, the company said.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs has launched a generic drug for treating high blood pressure, the company said.

Dr. Reddy's announced the launch of metoprolol succinate extended-release tablets in the 25-mg, 50-mg, 100-mg and 200-mg strengths. The drug will be available in bottle counts of 100 and 500.

The drug is a generic version of AstraZeneca's Toprol-XL, branded and generic versions of which had sales of about $1.13 billion during the 12-month period that ended in June, according to IMS Health.

July 18, 2012

Dr. Reddy's Labs has launched a generic version of a popular cholesterol drug.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic version of a popular cholesterol drug.

The company announced Wednesday the launch of atorvastatin calcium tablets in the 10-mg, 20-mg, 40-mg and 80-mg strengths.

The drug is a generic version of Pfizer's Lipitor, which had sales of slightly more than $8 billion during the 12-month period ended in March, according to IMS Health.

June 7, 2012

Dr. Reddy's Labs has launched a drug for treating Parkinson's disease, the company said Thursday.

HYDERABAD, India — Dr. Reddy's Labs has launched a drug for treating Parkinson's disease, the company said Thursday.

Dr. Reddy's introduced ropinirole hydrochloride extended-release tablets in the 2-mg, 4-mg, 6-mg, 8-mg and 12-mg strengths. The 2-mg, 4-mg and 6-mg strengths will be available in 30- and 90-count bottle sizes, while the other two strengths will be available in 30-count bottles.

The drug is a generic version of GlaxoSmithKline's Requip XL, which had sales of $58 million during the 12-month period ended in March, according to IMS Health.

June 6, 2012

A generic drug maker in India and a German pharmaceutical company will collaborate to develop biosimilars.

HYDERABAD, India — A generic drug maker in India and a German pharmaceutical company will collaborate to develop biosimilars.

Dr. Reddy's Labs and Merck KGaA subsidiary Merck Serono announced a partnership to develop biosimilar cancer treatments, most of them monoclonal antibodies, for global markets. Based in Darmstadt, Germany, Merck KGaA operates in the United States under the name EMD to distinguish itself from U.S. drug maker Merck.

May 21, 2012

Dr. Reddy's Labs has launched a generic version of a popular over-the-counter drug for treating heartburn, the company said Monday.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic version of a popular over-the-counter drug for treating heartburn, the company said Monday.

Dr. Reddy's announced the launch of lansoprazole delayed-release capsules in the 15-mg strength in pack sizes of 14, 28 and 42. The drug is a generic version of Novartis Consumer Health's Prevacid 24 HR capsule brand, which had sales of $115 million during the 12-month period ended in March, according to SymphonyIRI InfoScan Reviews.

May 18, 2012

Generic drug maker Dr. Reddy's Labs has launched a generic version of a drug used to prevent clotting of the blood.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs has launched a generic version of a drug used to prevent clotting of the blood.

Dr. Reddy's announced Friday the launch of clopidogrel tablets in the 75-mg and 300-mg strengths. The drug is a generic version of Plavix, made by Bristol-Myers Squibb and Sanofi. As one of the first companies to submit a completed regulatory application for the 300 mg strength of the drug, Dr. Reddy's received 180 days of market exclusivity for it.

April 24, 2012

Dr. Reddy's Labs has launched a generic version of an Eli Lilly drug used to treat psychiatric disorders, the company said Tuesday.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic version of an Eli Lilly drug used to treat psychiatric disorders, the company said Tuesday.

Dr. Reddy's announced the launch of olanzapine tablets in the 2.5-mg, 5-mg, 7.5-mg, 10-mg and 15-mg strengths.

The drug is a generic version of Zyprexa, used to treat schizophrenia and bipolar disorder. Generic and branded versions of the drug had sales of about $3.28 billion during the 12-month period ended in January, according to IMS Health.

March 5, 2012

Indian drug maker Dr. Reddy's has launched a drug designed to treat bipolar disorder and schizophrenia, the company said.

HYDERABAD, India — Indian drug maker Dr. Reddy's has launched a drug designed to treat bipolar disorder and schizophrenia, the company said.

The company announced the launch of ziprasidone hydrochloride capsules in the 20-mg, 40-mg, 60-mg and 80-mg strengths.

The drug is a generic version of Pfizer's Geodon, which had sales of $1.34 billion in 2011, according to IMS Health.

October 25, 2011

Dr. Reddy's Labs reported sales of $462 million for second quarter 2012 and $866 million for the first half of the fiscal year, according to an earnings statement released Tuesday.

HYDERABAD, India — Dr. Reddy's Labs reported sales of $462 million for second quarter 2012 and $866 million for the first half of the fiscal year, according to an earnings statement released Tuesday.

The Indian generic drug maker said the second-quarter sales represented a 21% increase over second quarter 2011. Sales from global generics were $329 million for the quarter, an 18% increase over second quarter 2011, driven mostly by growth in North America and Russia.

Profits for the quarter were $63 million, a 7% increase over second quarter 2011.

October 19, 2011

Mylan's India-based subsidiary is changing its name, Mylan said Wednesday.

PITTSBURGH — Mylan's India-based subsidiary is changing its name, Mylan said Wednesday.

The generic drug maker announced that Matrix Labs, based in Hyderabad, India, had formally changed its name to Mylan Labs.

"We are pleased to complete the name change from Matrix to a Mylan company and are excited to operate in India under one powerful brand," Mylan chairman and CEO Robert Coury said.

Mylan acquired Matrix in 2006.

August 30, 2011

Dr. Reddy’s Labs on Tuesday announced that it has launched its over-the-counter fexofenadine and pseudoephedrine extended-release tablets.

HYDERABAD, India — Dr. Reddy’s Labs on Tuesday announced that it has launched its over-the-counter fexofenadine and pseudoephedrine extended-release tablets.

Dr. Reddy’s will market the product, the equivalent to Allegra-D 24 Hour, under store-brand labels in the U.S. market, the company stated.

Quarterly sales of Allegra-D totaled $13.5 million for the 12 weeks ended Aug. 7, according to SymphonyIRI Group tabulating sales across food, drug and mass (minus Walmart) outlets.

July 15, 2011

The Food and Drug Administration has approved a generic anticoagulant drug made by Dr. Reddy’s Labs and Alchemia.

HYDERABAD, India — The Food and Drug Administration has approved a generic anticoagulant drug made by Dr. Reddy’s Labs and Alchemia.

Dr. Reddy’s and Brisbane, Australia-based Alchemia announced the FDA approval of fondaparinux sodium injection in the 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL and 10 mg/0.8 mL strengths. Alchemia owns the patents covering the process for synthesis of fondaparinux.

June 22, 2011

Generic drug maker Dr. Reddy’s Labs has launched its version of a popular antibiotic.

HYDERABAD, India — Generic drug maker Dr. Reddy’s Labs has launched its version of a popular antibiotic.

The company said its levofloxacin tablets in the 250-mg, 500-mg and 750-mg strengths have entered the market, following the Food and Drug Administration's approval of Dr. Reddy's abbreviated new drug application. Dr. Reddy's levofloxacin tablets in the 250-mg and 500-mg strengths are available in 50-count bottles, while the 750-mg strength bottle is available in 30-count bottles.

June 15, 2011

The Food and Drug Administration has issued a warning letter to Dr. Reddy’s Labs’ chemical manufacturing plant in Mexico, the company said Tuesday.

HYDERABAD, India — The Food and Drug Administration has issued a warning letter to Dr. Reddy’s Labs’ chemical manufacturing plant in Mexico, the company said Tuesday.

The drug maker said Dr. Reddy’s subsidiary Industrias Quimicas Falcon de Mexico, in Cuernavaca, received an FDA warning letter based on a November 2010 inspection where the regulatory agency found a number of manufacturing problems.

Dr. Reddy’s said it takes the warnings seriously and will respond to the FDA and work with the agency to resolve the problems.

June 7, 2011

Dr. Reddy's Labs has received regulatory approval from the Food and Drug Administration for generic versions of treatments for Alzheimer's disease, depression and breast cancer.

HYDERABAD, India — Dr. Reddy's Labs has received regulatory approval from the Food and Drug Administration for generic versions of treatments for Alzheimer's disease, depression and breast cancer.

The drug maker said that the FDA approved donepezil hydrochloride tablets, a generic version of Pfizer and Eisai's Arciept, in the 5-mg and 10-mg strengths for the treatment of Alzheimer's disease. Both strengths will be available in 30-, 90- and 500-count bottles.

May 31, 2011

Generic drug maker Mylan plans to give one of its subsidiaries a new name, the company said.

PITTSBURGH — Generic drug maker Mylan plans to give one of its subsidiaries a new name, the company said.

April 14, 2011

The Food and Drug Administration has approved Dr. Reddy's version of an allergy medication that recently received Rx-to-OTC switch approval, the generic drug maker said.

HYDERABAD, India — The Food and Drug Administration has approved Dr. Reddy's version of an allergy medication that recently received Rx-to-OTC switch approval, the generic drug maker said.

Dr. Reddy's fexofenadine HCl tablets are bioequivalent versions of Sanofi-Aventis’ Allegra, which received Rx-to-OTC switch approval from the FDA in January.

The fexofenadine HCl Rx market had branded and generic sales of approximately $452 million for the 12 months ended last December, according to IMS Health.

March 31, 2011

Indian generic drug maker Aurobindo has received two approvals from the Food and Drug Administration.

HYDERABAD, India — Indian generic drug maker Aurobindo has received two approvals from the Food and Drug Administration.

The company said Wednesday that it received approval for galantamine tablets in the 4-, 8- and 12-mg strengths. The drug is a version of Johnson & Johnson’s Alzheimer’s treatment Razadyne; various versions of the drug had sales of $41 million during the 12 months ended in September 2010, according to IMS Health.

March 30, 2011

Dr. Reddy’s Labs will assume ownership of a penicillin manufacturing site in Bristol, Tenn., from GlaxoSmithKline.

HYDERABAD, India — Dr. Reddy’s Labs will assume ownership of a penicillin manufacturing site in Bristol, Tenn., from GlaxoSmithKline.

The generic drug maker said it completed the acquisition of the facility and related product portfolio, including Augmentin and Amoxil brands. GSK will retain the existing rights for the aforementioned brands outside the United States.

Further financial terms and conditions of the transaction are not being disclosed.

March 29, 2011

Indian generic drug maker Dr. Reddy’s Labs has launched a generic treatment for seasonal allergies, the company said Tuesday.

HYDERABAD, India — Indian generic drug maker Dr. Reddy’s Labs has launched a generic treatment for seasonal allergies, the company said Tuesday.

Dr. Reddy’s announced the launch of levocetirizine tablets in the 5-mg strength. The drug is a generic version of UCB’s and Sanofi-Aventis’ Xyzal.

Levocetirizine had sales of about $238 million during the 12-month period ended in September 2010, according to IMS Health.

March 25, 2011

Indian generic drug maker may end its five-year stint as a retail pharmacy operator, according to published reports.

HYDERABAD, India — Indian generic drug maker may end its five-year stint as a retail pharmacy operator, according to published reports.

The Hindu Business Line reported Thursday that Natco was considering the sale of the SaveMart Pharmacy store in Lancaster, Pa.

February 1, 2011

A federal court has lifted an injunction that had prevented drug maker Dr. Reddy’s Labs from marketing a generic version of an allergy drug.

HYDERABAD, India — A federal court has lifted an injunction that had prevented drug maker Dr. Reddy’s Labs from marketing a generic version of an allergy drug.

Dr. Reddy’s said the U.S. District Court of New Jersey had filed a stipulation and order lifting the earlier injunction against the drug maker regarding the selling of a version of fexofenadine hydrochloride and pseudoephedrine hydrochloride tablets in the 180-mg/240-mg strength. The drug is a generic version of Sanofi-Aventis’ and Albany Molecular Research’s Allegra-D 24.

January 21, 2011

Indian drug maker Dr. Reddy’s Labs has launched a generic treatment for gastroesophageal reflux disease.

HYDERABAD, India — Indian drug maker Dr. Reddy’s Labs has launched a generic treatment for gastroesophageal reflux disease.

The company announced Thursday the launch of pantoprazole sodium delayed-release tablets in the 20-mg and 40-mg strengths. The drug is a version of Protonix, made by Wyeth, now part of Pfizer.

Pantoprazole sodium delayed-release tablets had sales of around $1.8 billion during the 12-month period ended in September 2010, according to IMS Health.

November 22, 2010

A generic drug maker has entered an agreement to purchase another drug maker's U.S. penicillin site ...

HYDERABAD, India A generic drug maker has entered an agreement to purchase another drug maker's U.S. penicillin site.

Dr. Reddy's and GlaxoSmithKline have inked a deal in which GSK will transfer ownership of its penicillin manufacturing site in Bristol, Tenn., and rights for the Augmentin and Amoxil brands in the United States to Dr. Reddy’s, an India-based drug maker.

This transaction is expected to close within the first half of calendar year 2011. Further financial terms and conditions of the agreement were not disclosed.